Table 1.
Combination of radiation and systemic therapy, level 1 evidence*
| Primary | Systemic agent | Advantage of combined treatment compared with radiation alone | References |
|---|---|---|---|
| Glioblastoma (brain) | Temozolomide | Improved OS | (3) |
| Head and neck | Cisplatin, cetuximab | Improved OS | (4), (5) |
| Lung | Cisplatin | Improved OS | (6) |
| Esophagus | 5FU + cisplatin | Improved OS | (7) |
| Stomach | 5FU + leucovorin | Improved OS compared with no treatment | (8) |
| Rectum | 5FU | Improved OS | (9) |
| Anus | 5FU + mitomycin | Improved local control | (10) |
| Cervix | Cisplatin | Improved OS | (11) |
| Prostate | Androgen deprivation therapy | Improved OS | (12) |
| Bladder | 5FU + mitomycin | Improved local control | (13) |
* OS = overall survival; 5FU = 5-fluorouracil.